Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
MarketBeat

Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals

Oculis (NASDAQ:OCS) said its two Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema did not meet their primary endpoints, and the company does not currently plan to pursue a U.S. Food and Drug Administration filing for the drug candidate in that indication.

Chief Executive Officer Riad Sherif said on the company’s conference call that Oculis was “naturally disappointed” with the outcome of the DIAMOND-1 and DIAMOND-2 studies. Both trials evaluated OCS-01 against vehicle in patients with diabetic macular edema, or DME, with the primary endpoint measured by change in best-corrected visual acuity, or BCVA, at week 52.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.